Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IONS
STRONG SELLIonis Pharmaceuticals, Inc. · Healthcare · United States · $9.3B · Avg Vol: $213M/d
COMPANY DESCRIPTION
Ionis Pharmaceuticals, Inc. is a leading biotechnology company pioneering RNA-targeted therapeutics, developing a broad pipeline of innovative medicines for severe and rare diseases using its proprietary antisense technology platform. The company possesses a unique and validated antisense technology platform with multiple approved drugs and a robust pipeline, providing a significant competitive advantage through its deep intellectual property portfolio. Ionis is a pioneer and leader in antisense oligonucleotide (ASO) drug discovery, offering a differentiated approach to treating a wide range of genetic and severe diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 587.4M | 787.6M | 705.1M | 943.7M | 17.1% | 1.1B | 889.9M | 1.4B | 21.5% |
| EPS | -1.90 | -2.56 | -3.04 | -2.38 | — | -2.01 | -2.62 | -1.07 | — |
| Shares | 142.1M | 144.3M | 157.9M | 163.3M | +15.0% | 165.3M | — | — | — |
| Debt | 1.4B | 1.5B | 1.4B | 2.1B | 14.7% | 2.6B | — | — | — |
| Equity | 572.9M | 386.7M | 588.4M | 489.1M | -5.1% | — | — | — | — |
| Op CF | -274.4M | -307.5M | -500.9M | -268.6M | — | -910.6M | — | — | — |
| Inv CF | -262.6M | -214.1M | -134.0M | -277.8M | — | — | — | — | — |
| Fin CF | -55.3M | 644.1M | 478.1M | 675.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IONS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals, Inc.(you) | $9.3B | 7 | STRONG SELL |
| SMMT | Summit Therapeutics Inc. | $10.9B | 9 | STRONG SELL |
| MANE | Veradermics, Incorporated | $4.6B | 8 | STRONG SELL |
| SRRK | Scholar Rock Holding Corporation | $5.7B | 13 | STRONG SELL |
| 0JAV.L | Insmed Incorporated | $18.9B | 10 | STRONG SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| PBLS | Parabilis Medicines, Inc. | $3.8B | 5 | STRONG SELL |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%